.

Browsing by Author "Evans, Douglas"

LAUR Repository

Browsing by Author "Evans, Douglas"

Sort by: Order: Results:

  • Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas 
    Overman, Micheal; Fogelman, David; Al-Kali, Aref; Crane, Christopher; Evans, Douglas; Abdalla, Eddie; Pisters, Peter; Kopetz, Scott; Eng, Cathy; Wolff, Robert (2015-11-17)
    We report 5 cases in which the recurrence of colorectal cancer (CRC) presented as a mass involving the duodenum and pancreas. The treatment approach for such recurrences is not standardized, and in particular, the benefits ...
  • Borderline Resectable Pancreatic Cancer 
    Katz, Matthew; Pisters, Peter; Evans, Douglas; Sun, Charlotte; Lee, Jeffrey; Fleming, Jason; Vauthey, Jean-Nicolas; Abdalla, Eddie; Crane, Christopher (2015-11-17)
    Background Patients with borderline resectable pancreatic adenocarcinoma (PA) include those with localized disease who have tumor or patient characteristics that preclude immediate surgery. There is no optimal treatment ...
  • Delayed Recovery after Pancreaticoduodenectomy 
    Abdalla, Eddie; Aloia, Thomas; Lee, Jeffrey; Vauthey, Nicolas; Wolff, Robert; Varadhachary, Gauri; Abbruzzese, James; Crane, Christopher; Evans, Douglas; Pisters, Peter (2015-11-12)
    Background Delayed recovery after pancreaticoduodenectomy (PD) is believed to preclude adjuvant therapy for approximately 30% of patients who undergo elective PD as initial treatment for pancreatic adenocarcinoma. This ...
  • Extrahepatic Bile Duct Adenocarcinoma 
    Borghero, Yerko; Crane, Christopher; Szklaruk, Janio; Oyarzo, Mauricio; Curley, Steven; Pisters, Peter; Evans, Douglas; Abdalla, Eddie; Thomas, Melanie; Das, Prajnan; Wistuba, Ignacio; Krishnan, Sunil; Vauthey, Nicolas (2015-11-16)
    Background Patients with resected extrahepatic bile duct adenocarcinoma who have microscopically positive resection margins and/or pathologic locoregional nodal involvement (R1pN1) have a high-risk of locoregional recurrence, ...
  • Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma 
    Raut, Chandrajit; Tseng, Jennifer; Sun, Charlotte; Wang, Huamin; Wolff, Robert; Crane, Christopher; Vauthey, Nicolas; Abdalla, Eddie; Lee, Jeffrey; Pisters, Peter; Evans, Douglas (2015-11-16)
    Objective: To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma. Summary Background ...
  • Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation 
    Abdalla, Eddie; Wayne, Jeffrey; Wolff, Edward; Crane, Christopher; Pisters, Peter; Evans, Douglas (2015-11-10)
    Pancreatic adenocarcinoma is the fifth leading cause of cancer-related death in the U.S. In spite of advancements in surgical treatment, nearly 80% of patients thought to have localized pancreatic cancer die of recurrent ...
  • Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma 
    Katz, Matthew; Wang, Huamin; Fleming, Jason; Sun, Charlotte; Hwang, Rosa; Wolff, Robert; Varadhachary, Gauri; Abbruzzese, James; Crane, Christopher; Krishnan, Sunil; Vauthey, Jean-Nicolas; Abdalla, Eddie; Lee, Jeffrey; Pisters, Peter; Evans, Douglas (2015-11-17)
    Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in these series. We evaluated long-term ...
  • One Hundred Years After “Carcinoid” 
    Yao, James; Hassan, Manal; Phan, Alexandria; Dagohy, Cecile; Leary, Colleen; Mares, Jeannette; Abdalla, Eddie; Fleming, Jason; Vauthey, Jean-Nicolas; Rashid, Asif; Evans, Douglas (2015-11-17)
    Purpose Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones. In this study, we examined the epidemiology of and prognostic factors for NETs, because a thorough examination of neither ...
  • Pancreaticoduodenectomy with vascular resection 
    Abdalla, Eddie; Tseng, Jennifer; Raut, Chandrajit; Lee, Jeffrey; Pisters, Peter; Vauthey, Nicolas; Gomez, Henry; Sun, Charlotte; Crane, Christopher; Wolff, Robert; Evans, Douglas (2015-11-11)
    Major vascular resection performed at the time of pancreaticoduodenectomy (PD) for adenocarcinoma remains controversial. We analyzed all patients who underwent vascular resection (VR) at the time of PD for any histology ...
  • Post-Therapy Pathologic Stage and Survival in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemoradiation 
    Estrella, Jeannelyn; Rashid, Asif; Fleming, Jason; Katz, Matthew; Lee, Jeffrey; Wolff, Robert; Varadhachary, Gauri; Pisters, Peter; Abdalla, Eddie; Vauthey, Jean-Nicolas; Wang, Hua; Gomez, Henry; Evans, Douglas; Abbruzzese, James; Wang, Huamin (2015-11-20)
    BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with ...
  • Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head 
    Varadhachary, Gauri; Wolff, Robert; Crane, Christopher; Sun, Charlotte; Lee, Jeffrey; Pisters, Peter; Vauthey, Jean-Nicolas; Abdalla, Eddie; Wang, Huamin; Staerkel, Gregg; Ross, William; Tamm, Eric; Bhosale, Priya; Krishnan, Sunil; Das, Prajnan; Ho, Linus; Xiong, Henry; Abbruzzese, James; Evans, Douglas (2015-11-17)
    Purpose We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarci ...
  • Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation 
    Katz, Matthew; Varadhachary, Gauri; Fleming, Jason; Wolff, Robert; Lee, Jeffrey; Pisters, Peter; Vauthey, Jean-Nicolas; Abdalla, Eddie; Sun, Charlotte; Wang, Huamin; Crane, Christopher; Lee, Jeffrey; Tamm, Eric; Abbruzzese, James; Evans, Douglas (2015-11-19)
    Purpose The role of carbohydrate antigen (CA) 19-9 in the evaluation of patients with resectable pancreatic cancer treated with neoadjuvant therapy prior to planned surgical resection is unknown. We evaluated CA 19-9 as ...
  • Subaquatic laparoscopy for staging of intraabdominal malignancy 
    Abdalla, Eddie; Barnett, Carlton; Pisters, Peter; Cleary, Karen; Evans, Douglas; Feig, Barry; Mansfield, Paul (2015-11-10)